FDA Releases New Framework for Evaluation of Digital Therapeutic Devices

By Caroline Brooks

The U.S. Food and Drug Administration issued updated guidance in December 2023 that defines digital therapeutics more precisely and outlines risk-based regulatory pathways for these products. The changes address the expanding role of software functions in medical devices and the need for consistent oversight across mobile applications and related tools. Primary FDA documents detail how these updates distinguish regulated digital therapeutics from general wellness products.

Updates to Guidance

The FDA revised its policy on device software functions to clarify premarket review expectations and postmarket monitoring for qualifying products. Higher-risk software receives stricter evaluation, while some low-risk functions may avoid certain requirements. This framework draws from the agency's existing guidance on mobile medical applications.

Definitions and Differentiation

Digital therapeutics now receive distinct classification when they meet criteria for treating or managing medical conditions through software. General wellness apps that make no disease-related claims fall outside this scope. The updated language separates these categories to reduce ambiguity in submissions.

Factors Behind the Changes

Growth in software-based health tools prompted the revisions, as developers increasingly integrate algorithms into therapeutic claims. The agency sought to align oversight with these trends while preserving safety standards. Industry input and technological shifts contributed to the timing of the December 2023 updates.

Alignment With Industry Trends

The guidance supports a broader move toward adaptive, risk-tiered regulation seen in other digital health areas. Stakeholders have noted that clearer pathways can reduce uncertainty during product development. This approach matches patterns in both U.S. and international efforts to handle software-driven devices.

Role of the Digital Health Center of Excellence

The FDA's Digital Health Center of Excellence supplies technical resources and policy navigation tools for these evaluations. It assists both regulators and developers in applying the new framework to specific products. The center maintains an online policy navigator that helps identify applicable requirements.

What this means

The framework establishes consistent criteria for classifying and reviewing digital therapeutics, which may affect how quickly new products reach evaluation stages. It maintains focus on patient safety through risk stratification without altering core statutory requirements.

Key takeaways

• The FDA's December 2023 updates provide distinct definitions for digital therapeutics separate from wellness products [2].
• Oversight follows a risk-based model that applies stricter review to higher-risk software functions [3].
• The Digital Health Center of Excellence supplies tools and assistance for navigating these pathways [1].
• Changes respond to increased development of software-based medical devices and mobile applications.
• Specific enforcement timelines and detailed mechanisms remain subject to further agency publications.

Limitations

The evidence covers only the scope of published guidance documents and does not include finalized enforcement details or long-term outcome data. Ongoing technological changes may require additional clarifications beyond the 2023 updates.

Last updated: September 4, 2026